SRx Health Solutions Inc. (SRXH) Key Metrics
SRXH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $24.0M
- Enterprise value
- $31.0M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.3
- Price / book
- 0.2
- EV / EBITDA
- 5.2
- Dividend yield
- —
- Beta
- —
SRXH key metrics, FY2015–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsSRXH returns How much profit the business earns on the capital it uses.
SRXH financial health Debt, liquidity and how easily interest is covered.
SRXH efficiency & capital use Working capital cycle and where the cash goes.
SRXH valuation history
SRXH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SRXH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SRXH cash returned to shareholders
SRXH price vs earnings per share
SRXH key metrics
FY2015–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | — | $2.73B | — | — | — | — | — | — | — |
| Enterprise value | — | — | $2.77B | — | — | — | — | — | — | — |
| Price / sales | — | — | 16.9 | — | — | — | — | — | — | — |
| Price / book | — | — | 181.1 | — | — | — | — | — | — | — |
| EV / sales | — | — | 17.1 | — | — | — | — | — | — | — |
| Earnings yield | — | — | −0.6% | — | — | — | — | — | — | — |
| Free cash flow yield | — | — | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $19.02 | $92.89 | $220.44 | $1,415.11 | $6,595.56 | $5,226.67 | $124,800.00 | $160,576.00 | $518,613.33 | $9,706.67 |
| Per share | ||||||||||
| Revenue per share | — | — | $13.04 | — | — | — | — | — | — | — |
| Earnings per share | — | — | −$1.22 | — | — | — | — | — | — | — |
| Operating cash flow per share | — | — | $0.01 | — | — | — | — | — | — | — |
| Free cash flow per share | — | — | $0.01 | — | — | — | — | — | — | — |
| Cash per share | — | — | $0.17 | — | — | — | — | — | — | — |
| Book value per share | — | — | $1.22 | — | — | — | — | — | — | — |
| Tangible book value per share | — | — | −$1.06 | — | — | — | — | — | — | — |
| Capex per share | — | — | $0.00 | — | — | — | — | — | — | — |
| Debt per share | — | — | $3.18 | — | — | — | — | — | — | — |
| Shares outstanding | — | — | 12.4M | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −628.6% | −1.7% | −39.2% | −3.6% | 20.1% | — | — | — | — | — |
| Return on invested capital (ROIC) | −137.6% | −21.9% | −9.5% | −1.4% | −85.2% | — | — | — | — | — |
| Return on assets (ROA) | −289.2% | −0.7% | −39.4% | −3.7% | 4.6% | −230.6% | — | — | — | — |
| Return on tangible assets | −535.7% | −1.6% | −109.8% | −11.0% | 6.3% | −303.9% | — | — | — | — |
| Free cash flow margin | −124.6% | −11.9% | 0.0% | −22.4% | −26.5% | −18.2% | — | — | — | — |
| Income quality (OCF / net income) | — | — | — | — | −3.97 | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $4.5M | $2.0M | $39.4M | $17.9M | $13.2M | $42.1M | $353,216 | $788,527 | $348,819 | — |
| Cash & short-term investments | $1.3M | $6.4M | $2.1M | $1.7M | $36.9M | $5.1M | $259,368 | $1,799 | $13,308 | — |
| Net debt | $3.2M | −$4.4M | $37.3M | $16.2M | −$23.7M | $37.0M | $93,848 | $786,728 | $335,511 | — |
| Debt / equity | 10.99 | 0.15 | 2.61 | 0.29 | 0.18 | — | — | — | — | — |
| Debt / assets | 0.53 | 0.09 | 0.94 | 0.51 | 0.13 | 0.64 | 1.30 | 29.12 | 12.14 | — |
| Net debt / EBITDA | — | −0.69 | — | 16.04 | −2.24 | — | — | — | — | — |
| Current ratio | 2.29 | 0.20 | 0.38 | 0.67 | 5.98 | 0.32 | 0.07 | 0.01 | 0.03 | — |
| Quick ratio | 1.71 | 0.15 | 0.30 | 0.49 | 5.27 | 0.23 | 0.07 | 0.00 | 0.02 | — |
| Interest coverage | -18.2 | -12.8 | -2.8 | -1.5 | -5.4 | -3.0 | -0.5 | -0.6 | -0.5 | -1.0 |
| Working capital | $4.6M | −$88.8M | −$40.4M | −$7.2M | $46.6M | −$47.3M | −$3.4M | −$1.5M | −$749,574 | — |
| Invested capital | $3.6M | $9.5M | $52.4M | $78.4M | $50.0M | $1.1M | −$3.3M | −$683,004 | −$407,052 | — |
| Tangible asset value | $407,000 | −$105.4M | −$57.0M | −$11.6M | $35.3M | −$76.4M | −$3.4M | −$1.5M | −$742,563 | — |
| Net current asset value | $131,000 | −$99.1M | −$45.7M | −$19.1M | $31.1M | −$78.9M | −$3.4M | −$1.5M | −$749,574 | — |
| Graham net-net per share | — | — | −$4.89 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $137,000 | $279,563 | — | — | $2.0M | — | — | — | — | — |
| Capex / revenue | 31.8% | 0.1% | 0.0% | 0.2% | 0.8% | 0.4% | 0.0% | 0.3% | 376,236.2% | — |
| Capex / operating cash flow | — | — | 18.6% | — | — | — | — | — | — | — |
| Capex / depreciation | 66.97 | 0.01 | 0.01 | 0.09 | 0.21 | 0.09 | — | — | 82.47 | — |
| Stock-based compensation / revenue | 68.4% | 9.9% | 1.8% | — | — | — | — | — | — | — |
| R&D / revenue | — | 0.3% | 0.1% | 0.7% | — | — | — | — | — | — |
| SG&A / revenue | 197.9% | — | 24.8% | 14.2% | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 403.6 | 63.7 | 11.8 | 23.7 | 45.3 | 39.7 | — | — | 342.2 | — |
| Days of inventory on hand | 242.3 | 59.0 | 13.7 | 24.6 | 57.2 | 31.5 | 20,500.0 | 11,786.8 | 1,064.2 | — |
| Days payables outstanding | 2,048.6 | 450.1 | 53.5 | 44.6 | 43.5 | 20.5 | 122,478.4 | 74,525.6 | 4,719.0 | — |
| Cash conversion cycle (days) | -1,402.7 | -327.3 | -28.0 | 3.7 | 59.1 | 50.7 | — | — | -3,312.7 | — |
| Receivables turnover | 0.90 | 5.73 | 30.95 | 15.39 | 8.05 | 9.20 | — | — | 1.07 | — |
| Payables turnover | 0.18 | 0.81 | 6.82 | 8.18 | 8.39 | 17.78 | 0.00 | 0.00 | 0.08 | — |
| Inventory turnover | 1.51 | 6.18 | 26.60 | 14.83 | 6.38 | 11.58 | 0.02 | 0.03 | 0.34 | — |
| Asset turnover | 0.42 | 1.55 | 4.21 | 1.39 | 0.71 | 1.66 | 0.00 | 0.08 | 0.00 | — |
| Average receivables | $7.2M | $8.8M | $5.2M | $6.0M | $7.3M | $5.9M | — | — | $59 | — |
| Average payables | $28.1M | $39.2M | $19.0M | $9.7M | $4.9M | $2.0M | $91,970 | $85,120 | $37,028 | — |
| Average inventory | $3.3M | $5.1M | $4.9M | $5.4M | $6.5M | $3.1M | $15,394 | $13,462 | $8,350 | — |
| Intangibles / total assets | 0.0% | 33.2% | 67.2% | 36.1% | 39.0% | 61.9% | 0.0% | 0.0% | 0.0% | — |
Computed from SRXH's annual financial statements (latest annual report filed December 5, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SRXH valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. SRx Health Solutions earned a return on equity of −628.6% and a return on invested capital of −137.6% in fiscal 2025. It ended the year with $4.5 million of debt and $1.3 million in cash and short-term investments, net debt of $3.2 million. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks.
See the SRXH income statement, the SRXH chart for price history, or the SRXH stock overview for the latest quote and news.
SRXH key metrics FAQ
What is SRx Health Solutions's P/E ratio?
SRx Health Solutions's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is SRx Health Solutions's return on equity?
SRx Health Solutions's return on equity (ROE) was −628.6% in fiscal 2025: net income of -$45.0 million on average shareholders' equity of $7.2 million.
What is SRx Health Solutions's ROIC?
SRx Health Solutions's return on invested capital was −137.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does SRx Health Solutions have?
SRx Health Solutions had total debt of $4.5 million at the end of fiscal 2025, a debt-to-equity ratio of 10.99.
Does SRx Health Solutions buy back its shares?
Yes. SRx Health Solutions spent $0.1 million on net share repurchases in fiscal 2025.
What is SRx Health Solutions's current ratio?
SRx Health Solutions's current ratio was 2.29 at the end of fiscal 2025: current assets were 2.29 times current liabilities.